(19)
(11) EP 3 307 241 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
19.12.2018 Bulletin 2018/51

(45) Mention of the grant of the patent:
26.09.2018 Bulletin 2018/39

(21) Application number: 16729525.2

(22) Date of filing: 08.06.2016
(51) International Patent Classification (IPC): 
A61K 9/06(2006.01)
A61K 47/32(2006.01)
A61P 27/06(2006.01)
 A61K 47/10(2017.01)
A61K 31/5575(2006.01)
(86) International application number:
PCT/EP2016/062990
(87) International publication number:
WO 2016/198434 (15.12.2016 Gazette 2016/50)

(54)

DRIPPABLE OPHTHALMIC BIMATOPROST GEL

TROPFBARES OPHTHALMISCHES BIMATOPROSTGEL

GEL FLUIDE OPHTALMIQUE DE BIMATOPROST

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Validation States:
MA

(30) Priority: 09.06.2015 EP 15171233

(43) Date of publication of application:
18.04.2018 Bulletin 2018/16

(73) Proprietor: MEDproject Pharma-Entwicklungs- und Vertriebsgesellschaft mbH
82041 Oberhaching (DE)

(72) Inventors:
  • POLZER, Heinz
    88138 Weißensberg (DE)
  • ELENA, Pierre-Paul
    06200 Nice (FR)
  • SENGE, Jürgen
    D-80539 München (DE)

(74) Representative: von Füner, Nicolai et al
Von Füner Ebbinghaus Finck Hano Patentanwälte Mariahilfplatz 3
81541 München
81541 München (DE)


(56) References cited: : 
EP-A2- 1 275 376
US-A1- 2011 319 487
 WO-A2-2012/163827
   
       
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).